L LUSIS
Live / Applied — Second extension granted (statement of use) (as of 16 Dec 2025)
What this means for you
Not registered yet, but its 20 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98458857
- Mark type
- Design + words
- Filed
- 20 Mar 2024
- Published for opposition
- 05 Nov 2024
- Attorney of record
- Steven K. Lee
Goods and services
- Class 005 — Pharmaceuticals: Injectable pharmaceuticals for treatment of anaphylactic reactions; Chemical reagents for medical purposes; Antibiotic tablets; Allergy tablets; Medicated water for the treatment of illnesses attributed to insufficient cellular energy; Medicated water for the treatment of allergies, cough, cold, flu, headache, pain; Medicated water for the treatment of infectious diseases, skin diseases and conditions, and internal diseases and conditions; Medicated water for the treatment of pain, nausea and muscle spasms; Medicated water-based solutions for treating skin infections and skin conditions; Medicated water for the treatment of gastrointestinal disorders; Antibiotic ointments; Anti-inflammatory ointments; Medicated ointments for treating dermatological conditions; Purified biochemical medical diagnostic reagents, namely, protein arrays, enzymes, and fluorescent dyes; Biochemical drugs for the treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; Diagnostic preparations for medical purposes; Chemico-pharmaceutical preparations in the nature of biological indicators, in-vivo diagnostic agents, in-vitro diagnostic reagents for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, and diseases related to the immune system and respiratory system; Chemical preparations in the nature of biological indicators, in-vivo diagnostic agents, in-vitro diagnostic reagents for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, and diseases related to the immune system and respiratory systems; Chemical preparations in the nature of biological indicators, in-vivo diagnostic agents, in-vitro diagnostic reagents for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, and diseases related to the immune system and respiratory system; Chemical reagents for medical or veterinary purposes
Owner
- LUSIS BIOSCIENCES, INC., HAYWARD, CA, US
- LUSIS BIOSCIENCES, INC., HAYWARD, CA, US
- Sansureus, Inc., Ontario, CA, US
Prosecution history
- 17 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Dec 2025 — SOU EXTENSION 2 GRANTED
- 16 Dec 2025 — SOU EXTENSION 2 FILED
- 16 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Jun 2025 — SOU EXTENSION 1 GRANTED
- 17 Jun 2025 — SOU EXTENSION 1 FILED
- 17 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Nov 2024 — PUBLISHED FOR OPPOSITION
- 16 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 28 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Sept 2024 — ASSIGNED TO EXAMINER
- 11 Sept 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP